Interindividual variability in imatinib metabolism in human liver microsomes and primary human hepatocytes: Impact of CYP2C8 and CYP3A phenotypes
- 3 November 2025
- journal article
- Published by Elsevier in Drug Metabolism and Disposition
- Vol. 53 (12) , 100196
Abstract
No abstract availableKeywords
Funding Information
- National Institute of General Medical Sciences (R35GM143044)
- School of Medicine, University of North Carolina at Chapel Hill
- University of North Carolina
- National Institutes of Health (S10OD032350 (2023)
- National Institutes of Health (S10RR024595)
This publication has 44 references indexed in Scilit:
- Impact of variation in CYP3A and CYP2C8 on tucatinib metabolic clearance in human liver microsomesDrug Metabolism and Disposition, 2025
- Influence of CYP2C8*3 and ABCG2 C421A genetic polymorphisms on trough concentration and molecular response of imatinib in Egyptian patients with chronic myeloid leukemiaCancer Chemotherapy and Pharmacology, 2024
- Effect of recombinant CYP3A4 variants and interaction on imatinib metabolism in vitroBiomedicine & Pharmacotherapy, 2024
- Genetic variation present in the CYP3A4 gene in Ni-Vanuatu and Kenyan populations in malaria endemicityDrug Metabolism and Pharmacokinetics, 2024
- Application of physiologically based pharmacokinetic modeling to understand real‐world outcomes in patients receiving imatinib for chronic myeloid leukemiaPharmacology Research & Perspectives, 2023
- Functional evaluation of vandetanib metabolism by CYP3A4 variants and potential drug interactions in vitroChemico-Biological Interactions, 2021
- Worldwide Distribution of Cytochrome P450 Alleles: A Meta‐analysis of Population‐scale Sequencing ProjectsClinical Pharmacology & Therapeutics, 2017
- CYP2C8 Genotype Significantly Alters Imatinib Metabolism in Chronic Myeloid Leukaemia PatientsClinical Pharmacokinetics, 2016
- CYP3A activity influences imatinib response in patients with chronic myeloid leukemia: a pilot study on in vivo CYP3A activityEuropean Journal of Clinical Pharmacology, 2010
- Sex differences in CYP3A activity using intravenous and oral midazolamClinical Pharmacology & Therapeutics, 2006